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Abstract
Wearable devices can capture objective day-to-day data about Parkinson’s Disease (PD).
This study aims to assess the feasibility of implementing wearable technology to collect data
from multiple sensors during the daily lives of PD patients. The Parkinson@home study is
an observational, two-cohort (North America, NAM; The Netherlands, NL) study. To recruit
participants, different strategies were used between sites. Main enrolment criteria were
self-reported diagnosis of PD, possession of a smartphone and age18 years. Participants
used the Fox Wearable Companion app on a smartwatch and smartphone for a minimum of
6 weeks (NAM) or 13 weeks (NL). Sensor-derived measures estimated information about
movement. Additionally, medication intake and symptoms were collected via self-reports in
the app. A total of 953 participants were included (NL: 304, NAM: 649). Enrolment rate was
88% in the NL (n = 304) and 51% (n = 649) in NAM. Overall, 84% (n = 805) of participants
contributed sensor data. Participants were compliant for 68% (16.3 hours/participant/day) of
the study period in NL and for 62% (14.8 hours/participant/day) in NAM. Daily accelerometer
data collection decreased 23% in the NL after 13 weeks, and 27% in NAM after 6 weeks.
Data contribution was not affected by demographics, clinical characteristics or attitude
towards technology, but was by the platform usability score in the NL (χ2 (2) = 32.014,
p<0.001), and self-reported depression in NAM (χ2(2) = 6.397, p = .04). The Parkinson@-
home study shows that it is feasible to collect objective data using multiple wearable sensors
in PD during daily life in a large cohort.
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Introduction
Parkinson’s Disease (PD) is a common neurodegenerative disease in which patients experience
both motor and non-motor symptoms[1]. Treatment is primarily based on the management
of symptoms by increasing dopamine levels through pharmacological therapy or surgery[2, 3].
Additionally, non-pharmacological therapies, such as physiotherapy, occupational therapy or
speech therapy, are available to support patients[4].
Although good results in the management of motor symptoms have been achieved, particu-
larly in the early stages of the disease[5, 6], two major problems hamper long-term treatment.
First, current pharmacological therapy is successful for a limited period. In the long term,
most patients develop unmanageable motor complications that can lead to worsening of qual-
ity of life[7]. Second, evaluation of day-to-day variations in PD symptoms is difficult when
relying solely upon periodic consultations by clinicians[8]. Therefore, more detailed, objective
and reliable measures during daily living could potentially improve the management of PD.
Wearable sensors have been used to assess PD-related symptoms continuously and longitu-
dinally during daily living[9–12]. Wearables may provide greater insight into a patient’s
disease status, allowing patients to self-manage their symptoms and monitor medication
responses[13–18]. Furthermore, wearable sensor data may improve our scientific understand-
ing of disease progression by showing changes in motor and non-motor symptoms over time,
furthering the development of digital biomarkers for disease progression[19].
While the potential value of wearable sensors for disease management and research are
increasingly becoming clear, various critical aspects of feasibility remain to be determined.
Only a few studies have rigorously investigated the feasibility and acceptability of using a wear-
able platform comprising a smartphone in combination to a smartwatch. Moreover, these
prior findings remained limited by the small sample sizes (biggest sample thus far: 40 PD
patients) [9, 13, 17, 18]. Therefore, we aimed to investigate the feasibility of using a wearable
platform in a much larger sample of PD patients, with a focus on recruitment success, attrition
rates, user compliance and system usability.
Methods
Between August/2015 and November/2016, a total of 953 PD patients from two cohorts
(n = 304 in The Netherlands (NL) and n = 649 PD in North America (Unites States and Can-
ada—NAM) participated in the Parkinson@Home feasibility study. To investigate the feasibil-
ity of the technology in different contexts, both cohorts used the same wearable platform, but
had distinct strategies for recruitment, retention and study period. These topics are described
separately (overview in Table 1).
Study design and population
The NL cohort. The population and study design applied in the NL are described in detail
elsewhere.[20] In short, participants were recruited from support groups, internet communi-
ties and through physiotherapists specialized in treating PD patients. Enrolment criteria
were: (1)30 years of age, (2) possession of a smartphone using an Android OS version 4.2
and (3) self-reported diagnosis of PD. No exclusion criteria were applied beyond enrolment
criteria.
All enrolled participants received a single medical examination, based on the “Parkinson’s
Progression Markers Initiative” (PPMI)[21]. This included the full MDS-UPDRS[22], the
Montreal Cognitive Assessment (MoCA)[23], and the Modified Schwab and England Activi-
ties of Daily Living Scale.[24] The medical examination was performed by specially trained
physiotherapists who are members of ParkinsonNet[25], a Dutch network of health
The Parkinson@Home study
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professionals specialised in PD management. At the end of the 13-weeks study period, all
enrolled participants evaluated the usability of the system through the System Usability Scale
(SUS)[26, 27], and were enquired about ability to use a smartphone (see APPENDIX). Finally,
participants had the option to continue using the platform or return the Pebble smartwatch.
The NAM cohort. Study recruitment for the NAM cohort was entirely virtual through
direct emails to subjects participating in the “Fox Insight online study”, Facebook advertise-
ments to targeted populations, and advertisements on Fox Trial Finder, a clinical trial match-
ing tool for people with PD.[28] Additional to the NL, the following enrolment criteria were
applied: (1)18 years of age and (2) participation in the Fox Insight Online Study[29]
(Table 1).
In order to enrol, interested participants had to first register in the Fox Insight study (if they
had not done so already). Through Fox Insight, each participant completed online surveys
about demographics, medical history, cognition, physical activity, symptoms and PD related
medications and surgeries. Once enrolled in the Fox Insight, participants were eligible to regis-
ter for the NAM cohort of the Parkinson@Home study on a separate webpage. These users
completed an online enrolment form which was reviewed by the study team to determine eligi-
bility. All study registrants received an email confirming their eligibility or non-eligibility. After
finishing the 6-weeks study period, participants had the option to continue using the platform.
Wearable platform
The Intel1 Pharma Analytics Platform used has been described in detail elsewhere.[20, 30]
Briefly, it consists of the Fox Wearable Companion app, used on both a smartwatch and
Table 1. Study design and procedure overview at the two cohorts.
The Netherlands North America
Recruitment strategies Through Internet communities ✓ ✓
Through support groups ✓ -
Through physiotherapists ✓ -
Enrolment criteria  30 years old ✓ -
Dutch resident ✓ -
Smartphone using Android OS version 4.2 or higher ✓ ✓
Self-reported PD ✓ ✓
 18 years old - ✓
Registered for Fox Insight study - ✓
English-speaking Canadian or United States resident - ✓
Exclusion criteria None ✓ ✓
Consent process Informative email ✓ ✓
Online digital consent form ✓ ✓
Study kit Pebble smartwatch ✓ ✓
Installation guide ✓ ✓
User manuals ✓ ✓
Clinical evaluations Assessment by physical therapist ✓ -
Fox Insight online self-assessment surveys - ✓
Study duration Minimum of 6 weeks - ✓
Minimum of 13 weeks ✓ -
Instruction for device usage Minimum of 5 hours a day - ✓
24 hours, 7 days a week ✓ -
Support model Call-center during working hours ✓ ✓
Technical support calls for non-data contributors ✓ -
Support emails for non-contributors - ✓
Usability questionnaire - ✓ -
https://doi.org/10.1371/journal.pone.0189161.t001
The Parkinson@Home study
PLOS ONE | https://doi.org/10.1371/journal.pone.0189161 December 20, 2017 3 / 15
Dolors Terricabras are employed by UCB. This
affiliation does not alter our adherence to PLOS
ONE policies on sharing data and materials. Max A
Little received research funding support from the
Michael J Fox Foundation and UCB. Heribert
Baldus is employed by Philips Research. This
affiliation does not alter our adherence to PLOS
ONE policies on sharing data and materials.
Bastiaan R Bloem has served as an editorial board
member of Movement Disorders, currently serves
as an editorial board member of Physiotherapy
Canada, is Associate Editor for the Journal of
Parkinson’s disease, received honoraria from
serving on the scientific advisory board for Danone
and Zambon, has received fees for speaking at
conferences from AbbVie and Teva, and received
research support from the Netherlands
Organization for Scientific Research, the Michael J
Fox Foundation, the Prinses Beatrix Foundation, the
Stichting Parkinson Fonds, the National Parkinson
Foundation and the Parkinson Vereniging. Marjan J
Faber received grant support from the Michael J
Fox Foundation, the Stichting Parkinson Fonds,
Philips Research, The Netherlands Organisation for
Health Research and Development and Health
Holland.
smartphone, and a cloud environment. In this study, a Pebble smartwatch, was used together
with the patients’ Android phones. 50 Hz accelerometer data were collected continuously
from the smartwatch and streamed to the smartphone.
Sensor analysis algorithms are applied to the aggregated (30 second interval) smartwatch
accelerometer data in the app to estimate outcomes (i.e. levels of activity, tremor and move-
ment during sleep). These estimated quantities are transmitted, via Wi-Fi or mobile data, to a
cloud environment. They are also presented to the user by graphs and summary reports within
the app. Additionally, users are able to set medication reminders, report actual medication
intake and rate their symptoms (e.g. tremor, dyskinesia, rigidity, bradykinesia) within the
mobile app (Fig 1). Both estimated outcomes and patients reported outcomes (PROs) are
stored in the cloud environment.
Study procedures at both cohorts
Participants from both cohorts provided electronic consent and received a research kit con-
taining a Pebble smartwatch, an installation guide and user manuals. Next, participants
installed the Fox Wearable Companion App on their devices and were asked to wear the
smartwatch and keep their smartphone with them as much as possible on either a 24/7 basis
for 13-weeks study period (NL) or for a minimum of 5 hours a day, 7 days a week, for a
6-weeks study period (NAM). Additionally, participants reported their medication intake (i.e
medication name and doses) and PD symptom severity using the app. A helpline was available
during the study period for technical support. Support calls or emails were sent to participants
from whom data were not collected for more than seven consecutive days.
Fig 1. (a) Fox Wearable Companion app main screen; (b) Fox Wearable Companion app activity graph; (c) Fox Wearable Companion app
movement during sleep graph; (d) Fox Wearable Companion app symptom self-reports. “Reprinted from [Intel and Michael J Fox Foundation] under a
CC BY license, with permission from [INTEL®], original copyright [2017].
https://doi.org/10.1371/journal.pone.0189161.g001
The Parkinson@Home study
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Outcome definitions and statistical analysis
Feasibility assessment included recruitment, attrition, compliance and system usability.
Recruitment success was analysed by (1) the total number of enrolled participants and (2) the
number of eligible registrants that did not complete the informed consent. Compliance, simi-
lar to previous studies[31, 32], was calculated as the median percentage of the study period
where accelerometer data were collected. Attrition rate, based upon Eysenbach et al. [33], were
measured by (1) decrease in the daily percentage of collected accelerometer data during each
study period and (2) decrease in the number of participants contributing accelerometer data.
Finally, system usability was measured by the median total score on the System Usability Scale.
We investigated the relationship between self-reported demographics, clinical data, ability
to use a smartphone (S1 File), System Usability score and the percentage of accelerometer data
collected to identify factors that influence compliance levels. Participant demographic and
clinical characteristics were grouped into categories either following previously described liter-
ature (presence of depression[34]; presence of cognitive impairment[23]) or by convenience
(age; educational level: a measure of the last completed level of education where low education
was equal to high school or lower levels, middle education was equal to bachelor, and high
education was equal to master or higher levels; Hoehn & Yahr stage and Modified Schwab and
England scale). Because compliance was not normally distributed, the median and quartiles
were used to divide participants into three compliance groups (low, middle and high). The
first quartile was the cut-off for the low compliant group and third quartile for the high com-
pliant group. Depending on the distribution of other variables in the analysis, either Chi-
square, Fisher’s Exact Test or Kruskal-Wallis were used to investigate significant differences
between compliance groups considering demographics, clinical characteristics, ability to use a
smartphone and System Usability score.
Ethics standards
This study was conducted in compliance with the Ethical Principles for Medical Research
Involving Human Subjects, as defined in the Declaration of Helsinki. The study protocol and
communication materials were approved by the local ethics committee (NL: CMO Arnhem-
Nijmegen; NL53034.091.15; NAM: New England IRB: 15–046).
Results
Recruitment and sample characteristics
In the NL cohort, 347 eligible PD patients were invited to participate. Among those invited, 43
refused to participate. The main refusal reasons were “Study protocol seems too burdensome”
(44%, n = 19), followed by “Personal circumstances” (33%, n = 14). A total of 304 patients
(enrolment rate = 88%) were enrolled.
In the NAM cohort, from the 866 participants of the Fox Insight study who received a direct
invitation to participate, 306 were enrolled (6% were ineligible). 344 additional participants
were included from the remaining recruitment channels, with varied ineligibility rates. A total
of 649 registrants (enrolment rate = 51%) were enrolled.
In both cohorts, 953 participants were enrolled. From them, 805 were data contributors
(participants that contributed at least one accelerometer data point during study period). Anal-
ysis of the demographic characteristics of both cohorts showed that, in comparison to NA, the
NL cohort presented more men (χ2 (1) = 9.5146, p<0.01); older (χ2 (2) = 16.435, p = 0.001)
and higher educated (χ2 (2) = 25.270, p<0.001) PD included participants. The characteristics
of all participants are presented in Table 2.
The Parkinson@Home study
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Technical support to participants
In both cohorts, the helpdesk consisted of two research assistants, available for 20 hours (NL)
and 40 hours (NAM) per week. The actual workload was dependent on: (1) the number of
participants simultaneously enrolled in the trial; and (2) the occurrence of bugs in the app or
server downtime. The most frequent and time-consuming problems were: (1) Bluetooth dis-
connection between the smartwatch and the smartphone and (2) questions regarding the med-
ication report, especially in the first weeks of participation.
Compliance
Among both cohorts, 85% (n = 805 of 953 enrolled) of participants were data contributors. In
the NL, 291 data-contributors collected data for a median of 1,478 hours each in the 13-weeks,
Table 2. Demographic and disease related characteristics of participants.
The Netherlands North America Total
Data
contributors
(n = 291)*
Non-
compliant
(n = 13)*
p-
value
Data
contributors
(n = 514)*
Non-
compliant
(n = 135)*
p-
value
Data
contributors
(n = 805)*
Non-
compliant
(n = 148)*
Sex Men 168 (65%) - NA 260 (53%) 25 (51%) .763 454 (58%) 25 (51%)
Age 50 29 (10%) 1 (8%) .523 101 (21%) 11 (22%) .676 130 (17%) 12 (19%)
51–69 207 (72%) 8 (61%) 310 (63%) 28 (57%) 517 (66%) 36 (58%)
70 53 (18%) 4 (31%) 81 (16%) 10 (20%) 134 (17%) 14 (23%)
Education Level Low 51 (20%) NA NA 168 (35%) 21 (44%) .477 219 (30%) 21 (44%)
Middle 103 (40%) NA NA 187 (39%) 16 (33%) 290 (39%) 16 (33%)
High 101 (40%) NA NA 126 (26%) 11 (22%) 227 (31%) 11 (22%)
Disease severity 0/1 73 (30%) 1 (100%) NA 235 (49%) 21 (47%) .580 308 (43%) 22 (48%)
2 127 (53%) 0 134 (28%) 10 (22%) 261 (36%) 10 (22%)
3 34 (14%) 0 98 (20%) 13 (29%) 132 (18%) 13 (29%)
4/5 6 (2%) 0 13 (3%) 1 (2%) 19 (3%) 1 (2%)
Depression1 No 238 (97%) - NA 346 (70%) 26 (53%) .013 584 (79%) 26 (53%)
Cognitive impairment2 No (>26) 124 (53%) 1 (100%) NA NA NA NA 124 (53%) 1 (100%)
Independency level3 70 36 (15%) 0 NA NA NA NA 36 (15%) 0
71–80 51 (22%) 0 NA NA 51 (22%) 0
81–90 109 (46%) 1 (100%) NA NA 109 (46%) 1 (100%)
91 41 (17%) 0 NA NA 41 (17%) 0
How easy is for you to
use a smartphone?
Very easy 59(22%) 0 .211 NA NA NA 59(22%) 0
Easy 117(44%) 3(50%) NA NA 117(44%) 3(50%)
Neither easy
nor difficult
64(22%) 1 (17%) NA NA 64(22%) 1 (17%)
Difficult 20(7%) 2 (33%) NA NA 20(7%) 2 (33%)
Very difficult 6(2%) NA NA 6(2%)
MDS-UPDRS (Median) 52.5 (QR 35–
69)
22 - NA NA 52.5 (QR 35–
69)
22
*Number of missing values differed across variables; only valid percentages are reported.
SES: Socioeconomic status; Disease severity: assessed with Hoehn and Yarh stages at the NL cohort and estimated from self-reported at NAM cohort;
MDS-UPDRS: Movement Disorders Society—Unified Parkinson’s Disease Rating Scale.
1
-Depression was assessed with the Geriatric Depression Scale at NL and self-reported on NAM site;
2
-Cognitive impairment was assessed using the Montreal Cognitive Assessment,
3
-Independency level was measured by Modified Schwab and England Activities of Daily Living Scale.
NA = not assessed. QR: 1st and 3rd quartiles.
https://doi.org/10.1371/journal.pone.0189161.t002
The Parkinson@Home study
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with quartile ranges (1st and 3rd QR) of 888 to 1,827 hours. In NAM, 514 data contributors
collected a median of 621 hours (1st QR: 286 and 3rd QR: 828 hours) each during the 6-weeks.
Compliance rates for each cohort were 68% (1st and 3rd QR: 41%-83%) equal to 16.3 hours/
participant/day in the NL and 62% (1st and 3rd QR: 28%-82%) equal to 14.8 hours/participant/
day in NAM (Fig 2).
Attrition
In the NL, 13 participants (4% of all NL enrolled participants) did not contribute any data dur-
ing the study period and were thus non-compliant. In NAM, this number was 135 (21% of all
NAM enrolled participants). Additionally, 82 (27% of all enrolled) data-contributors in the NL
became non-compliant during the study period. The primary known reasons (n = 47) were
“Personal circumstances” (38%, n = 18) and “System too complex/System related issues” (34%,
n = 16). For the NAM cohort, although reasons were unknown, this number was 89 (17% of all
enrolled).
The attrition in the median percentage of sensor data collected daily varied between
cohorts. In the NL, the attrition rate was 23% after 13-weeks’ study period. In the NAM, attri-
tion was 27% after 6-weeks’ study period (Fig 3).
Attrition in participation was tracked during and beyond the compulsory study period for
each cohort. he number of participants decreased rapidly after the end of the study period in
the NL cohort. A more gradual attrition in participation occurred in the NAM cohort (Fig 4).
Ninety-six percent (n = 280) of data-contributors in the NL reported their medication
through the app, while 78% (n = 404) did so in NAM. On average, data-contributors who used
medication reports reported 351±217 medication intakes during the 13-week study period in
Fig 2. Distribution of compliance among all enrolled participants in the NL (n = 304-black) and NAM (n = 649-white) study
cohorts.
https://doi.org/10.1371/journal.pone.0189161.g002
The Parkinson@Home study
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the NL and 127±113 over 6-week study period in NAM. Both cohorts showed a low and non-
exponential attrition in medication report, similar to the attrition showed in compliance with
the accelerometer data (data not shown).
System usability
In the NL cohort, 256 participants completed the System Usability Scale (response rate = 71.4%).
The median score was 62.5 (1st and 3rd QT 47.5–72.5), which classifies the wearable platform in
a category between “Ok” and “Good” (Fig 5).
Factors related to compliance
After grouping all NL data-contributors into compliance groups, analysis reveals no significant
differences in the distribution of demographics, clinical characteristics and ability to use a
smartphone between these groups. However, Kruskal-Wallis analysis demonstrates that the
System Usability score reported is significantly different between the groups (χ2 (2) = 32.014,
p<0.001). The mean rank score is 84.8 for the low compliant group, 130.8 for the middle com-
pliant group and 160.0 for the high compliant group, which indicates that participants in the
high compliant group provided a higher usability score to the system.
For the NAM cohort, analysis shows that demographics and clinical characteristics between
the three compliance groups was comparable, except for a trend regarding self-reported
depression (χ2(2) = 6.397, p = .04). This result indicates that a slightly higher number of self-
reported depressed patients are in the low compliant group (Table 3).
Fig 3. Attrition in compliance per day for NL (n = 291, black) and NAM participants (n = 514, gray) during the follow up period.
https://doi.org/10.1371/journal.pone.0189161.g003
The Parkinson@Home study
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Discussion
This study assessed the feasibility of using a wearable platform for long-term data collection in
a large sample of PD patients. We focused on: recruitment success, attrition rates, compliance
End of follow-up
End of follow-up
Fig 4. Number of participants actively collecting sensor data at the NL (gray) and NAM (black) cohorts during and after the follow-
up period (total initial n = 805).
https://doi.org/10.1371/journal.pone.0189161.g004
Fig 5. SUS scoring of the Fox Wearable Companion platform (smartwatch with smartphone app) as rated by participants.
https://doi.org/10.1371/journal.pone.0189161.g005
The Parkinson@Home study
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and system usability. Enrolment rate was 88% (n = 304) in the NL and 51% (n = 649) in NAM.
Nearly 85% of all enrolled participants contributed sensor data during the study period.
Median compliance rate was 68% (16.3 hours/participant/day) in the NL, and 62% (14.8
hours/participant/day) in NAM. The rate of accelerometer data collected each day declined
23% in the NL after 13-weeks of study period, and 27% in NAM after 6-weeks of study period.
The distribution of demographics, clinical characteristics and ability to use a smartphone did
not differ across compliance groups in the NL, but System Usability score did differ. For the
Table 3. Distribution of data-contributors’ characteristics and influence on compliance for the NL and NAM cohorts.
The Netherlands North America
Low
compliance
(n = 73)*
Middle
compliance
(n = 146)*
High
compliance
(n = 72)*
p-
value
Low
compliance
(n = 128)*
Middle
compliance
(n = 256)*
High
compliance
(n = 129)*
p-
value
Sex Men 39 (71%) 84 (64%) 44 (65%) .634 64 (56%) 133 (54%) 62 (49%) .504
Age 50 7 (10%) 15 (10%) 7 (10%) .954 30 (26%) 49 (20%) 22 (17%) .414
51–69 51 (70%) 103 (71%) 53 (75%) 67 (57%) 161 (65%) 81 (64%)
70 15 (20%) 27 (19%) 11 (16%) 20 (17%) 36 (15%) 24 (19%)
Education Level Low 11 (20%) 23 (17%) 17 (25%) .684 46 (41%) 84 (35%) 38 (31%) .144
Middle 21 (38%) 45 (84%) 24 (35%) 43 (38%) 86 (35%) 57 (46%)
High 23 (42%) 51 (39%) 27 (40%) 24 (21%) 73 (30%) 29 (23%)
Disease severity 0+1 15 (42%) 37 (28%) 21 (30%) .555 50 (44%) 121 (50%) 64 (52%) .45
2 15 (42%) 72 (54%) 40 (57%) 30 (26%) 66 (27%) 38 (31%)
3 6 (16%) 20 (15%) 8 (11%) 30 (26%) 48 (19%) 19 (15%)
4+5 0 (0%) 5 (4%) 1 (1%) 4 (4%) 7 (3%) 2 (2%)
Depression1 No (<6) 36(100%) 135 (98%) 67 (94%) .285 74 (63.2%) 172 (70%) 99 (78%) .044
Cognitive impairment2 No (>26) 16 (47%) 74 (56%) 34 (50%) .584 - - - -
Level of
independency3
70 5 (14%) 21 (16%) 10 (15%) .164 - - - -
71–80 13 (36%) 30 (23%) 8 (12%) - - -
81–90 13 (36%) 61 (46%) 35 (52%) - - -
91 5 (14%) 21 (16%) 15 (22%) - - -
How easy is for you to
use a smartphone?
Very easy 12 (19%) 33 (24%) 14 (21%) .065 - - - -
Easy 27 (44%) 60 (44%) 30 (44%) - - -
Neither easy
nor difficult
14 (23%) 27 (20%) 23 (34%) - - -
Difficult 5 (8%) 14 (10%) 1 (2%) - -
Very difficult 4 (6%) 2 (2%) (0%) - - - -
MDS-UPDRS6
(median)
49 55 48 .55 - - - -
SUS6 (median) 50 65 70 <0.001 - - - -
*Missing values varied across variables.
Red is significant at .05; green is significant at .001.
SES: Socioeconomic status; Disease severity: assessed with Hoehn and Yarh stages at the NL cohort and estimated from self-reported at NAM cohort;
GDS: Geriatric Depression Scale; MoCA: Montreal Cognitive Assessment, MDS-UPDRS: Movement Disorders Society—Unified Parkinson’s Disease
Rating Scale, SUS: System Usability Scale.
1
-Depression was assessed with the Geriatric Depression Scale at NL and self-reported on NAM;
2
-Cognitive impairment was assessed using the Montreal Cognitive Assessment;
3
-Independency level was measured by Modified Schwab and England Activities of Daily Living Scale;
4
–Pearson Chi-Square;
5
–Fisher’s Exact Test;
6
-Kruskal-Wallis
https://doi.org/10.1371/journal.pone.0189161.t003
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NAM, the distribution of demographics and clinical characteristics between the compliance
groups was comparable, except for self-reported depression status.
The high compliance in this study shows that it is feasible for people with PD to use this
wearable platform in a real-world environment for many months. Although the feasibility of
using consumer wearable sensors to monitor PD symptoms has been previous reported[9, 13,
17, 18, 31, 35], this is the first rigorous observational study to investigate the feasibility of a wear-
able platform comprising a smartwatch combined with a smartphone in such a large patient
group (the largest prior study included only 40 patients). Additionally, the small differences in
study protocols across cohorts allowed us to observe the impact of varying usage instructions
on compliance. Comparing the feasibility results obtained in this study to other studies, where
either mobile apps were used in large cohorts[36] or e-health technologies were use[37, 38] d,
we achieved a high compliance together with small and non-exponentially decreasing attrition
rate, even though exponential decrease in compliance is the norm in these sort of studies[33].
This unusually high compliance rate may be attributed to the “passive” data collection. In
this case, little or no interaction with the technology is required in order to collect sensor data.
Participants using the Parkinson@Home wearable platform, other than reporting their medi-
cation intake when reminded by the alarm (which was widely perceived as a service, instead
of a burden), did not need to interact actively with the smartphone or smartwatch. In another
similar smartphone-based study where “active”, “task-based” monitoring was used (that is,
where participants needed to perform certain specific tasks, at regular intervals prompted by
the platform)[36], a more typical high and exponential attrition rate was observed. While it is
difficult to draw firm conclusions from this comparison (because the two platforms are some-
what different), we suspect that periodic and long interaction by users may increase attrition,
leading to attrition rates seen in paper-based diaries[39]. The low and non-exponential attri-
tion seen in the medication reports, a quick and less burdensome task, strengthened this
conclusion. Thus, passive monitoring, where little to no interaction with the technology is
required, may lead to better overall compliance rates.
Despite the potential influence of age, gender and PD-related impairment (i.e. physical or
cognitive) on compliance, our results showed that overall disease severity, MDS-UPDRS
scores, independency level or cognitive impairment, did not influence compliance, which sug-
gests that this platform could be used by most PD patients. The unique design of the Parkin-
son@home study can partially explain this result. The presence of a personalized support
centre, which was previously described as an effective strategy to improve retention of partici-
pants[33], may have increased patients’ confidence in using the system and have compensated
for any disease-related difficulties.
Moreover, the “pro-active” support model, with scheduled calls to participants who showed
signs of low compliance, may have boosted compliance by providing a quick resolution of
technical interruptions, and addressed any apathy towards participation caused by technology
difficulties. This support is even more important because compliance is compromised in
participants that reported low System Usability scores. Therefore, in order to achieve high
compliance while using smartphone/smartwatch wearable platforms to measure PD related
symptoms at home, it is beneficial to: (1) improve the platform’s usability, (2) reduce the num-
ber of technical issues, and (3) run a personalized support centre that can provide guidance to
deal with possible technology related issues that participants may encounter.
Limitations
The Parkinson@Home study did have a few limitations. First, this is one of the first large-scale
cohort studies using consumer wearable sensors in PD, with a long study period duration (i.e.
The Parkinson@Home study
PLOS ONE | https://doi.org/10.1371/journal.pone.0189161 December 20, 2017 11 / 15
up to 13 weeks). However, the study sample consisted only of PD patients that possessed a
smartphone, thus introducing a possible selection bias, e.g. towards more highly educated sub-
jects. Although smartphone penetration in the NL and NAM is high[40, 41], participants may
not reflect the majority of PD patients living in the Netherlands, North America, or elsewhere
in the world. Furthermore, when compared to the general PD population[42], participants
were mainly young with a mild disease impairment and with some degree of cognitive
impaired. Even though these variables showed no obvious influence on compliance, a more
impaired population may need more personal support in order to maintain compliance.
Future studies should aim for a more stratified population in order to further confirm the lack
of influence across the full range of disease severity in the compliance with wearable sensors
among PD patients. Second, the present results only apply to the use of two specific consumer
grade devices (i.e. smartphone and smartwatch). Although consumer grade devices bring
potential advantage over the use of dedicated medical devices, it is unknown whether our
promising feasibility results would generalize to dedicated medical devices which are often
more expensive and less user-friendly.
Conclusion
In conclusion, the Parkinson@home trial showed that it is feasible to deploy a technology plat-
form consisting of consumer-grade wearable and mobile devices for long-term data collection
in a large and geographically diverse PD population. Importantly, compliance was comparable
for patients with a range of backgrounds, including men and women, different ages, and some
variations in disease severity. These findings suggest that wearables may offer a promising
approach to overcome the limitations in monitoring disease status and progression of mildly
impaired PD patients in a real-life environment. The platform here used is a promising and
practical approach to capturing large amounts of sensor data from many participants by pas-
sive means, without much need for interaction with the technology. In the future, these prop-
erties may position sensor technologies as effective tools for monitoring PD and the “lived
experience” of PD patients.
Supporting information
S1 File. Scale created by the researchers to measure ability to use a smartphone.
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